1932

Abstract

Abstract

The AMP-activated protein kinase (AMPK) system is a regulator of energy balance at both the cellular and whole-body levels that, once activated by low energy status, effects a switch from ATP-consuming anabolic pathways to ATP-producing catabolic pathways. It now appears to be the major target for two existing classes of drug used to treat type 2 diabetes, i.e., the biguanides and thiazolidinediones. However, in both cases these activate AMPK indirectly, and an interesting question concerns whether a drug that directly activated AMPK would retain the therapeutic benefits of the existing drugs while eliminating unwanted side effects. AMPK activators also now have potential as anticancer drugs.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.pharmtox.47.120505.105304
2007-02-10
2024-03-29
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.pharmtox.47.120505.105304
Loading
/content/journals/10.1146/annurev.pharmtox.47.120505.105304
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error